NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.

Autor: Chang M; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Sherief M; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Ioannou M; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Chinnasamy V; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Chen L; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Frost M; Infixion Bioscience, Inc., San Diego, CA, USA., Mattson-Hoss M; Infixion Bioscience, Inc., San Diego, CA, USA., Sarnoff H; Infixion Bioscience, Inc., San Diego, CA, USA., Kamson DO; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Holdhoff M; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Mukherjee D; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Bettegowda C; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Rincon-Torroella J; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Croog V; Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Huang P; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Rodriguez FJ; Division of Neuropathology, University of California, Los Angeles, Los Angeles, CA, USA., Lucas CG; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Schreck KC; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ksolt1@jhmi.edu.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ksolt1@jhmi.edu.

Publikováno v: Acta neuropathologica communications [Acta Neuropathol Commun] 2024 Oct 29; Vol. 12 (1), pp. 172. Date of Electronic Publication: 2024 Oct 29.

A brave new framework for glioma drug development.

Autor: Hotchkiss KM; The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Karschnia P; Department of Neurosurgery, Friedrich-Alexander University, Erlangen, Germany; Ludwig-Maximilians-University, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany., Schreck KC; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Geurts M; Department of Neurology, Erasmus MC Cancer Center, Rotterdam, Netherlands; Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, Netherlands., Cloughesy TF; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Huse J; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duke ES; Division of Oncology 2, Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA., Lathia J; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA., Ashley DM; The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Nduom EK; Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA., Long G; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Mater and Royal North Shore Hospitals, Sydney, NSW, Australia., Singh K; The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Chalmers A; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Ahluwalia MS; Baptist Health South Florida, Miami, FL, USA., Heimberger A; Department of Neurological Surgery, Northwestern University, Chicago, IL, USA., Bagley S; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Todo T; Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Verhaak R; Department of Surgical Neuro-Oncology, Yale University, New Haven, CT, USA., Kelly PD; Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA., Hervey-Jumper S; Department of Neurological Surgery, UCSF Brain Tumor Center, University of California San Francisco, San Francisco, CA, USA; Weill Institute for Neuroscience, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., de Groot J; Department of Neurological Surgery, UCSF Brain Tumor Center, University of California San Francisco, San Francisco, CA, USA; Weill Institute for Neuroscience, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Patel A; The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Fecci P; The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Parney I; Department of Neurological Surgery, Mayo Clinic, Rochester, MN, USA., Wykes V; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Neurosurgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Watts C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Neurosurgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Burns TC; Department of Neurological Surgery, Mayo Clinic, Rochester, MN, USA., Sanai N; Barrow Neurological Institute, Phoenix, AZ, USA., Preusser M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Tonn JC; Ludwig-Maximilians-University, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany., Drummond KJ; Department of Neurosurgery, Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Surgery, University of Melbourne, Parkville, VIC, Australia., Platten M; Department of Neurology, Mannheim Center for Translational Neuroscience, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany; Clinical Cooperation Unit Brain Tumor Immunology (D170), German Cancer Research Center (DKFZ), Heidelberg, Germany., Das S; Division of Neurosurgery, University of Toronto, Toronto, ON, Canada., Tanner K; National Brain Tumor Society, Newton, MA, USA., Vogelbaum MA; H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Weller M; Department of Neurological Surgery, Mayo Clinic, Rochester, MN, USA; Department of Neurology, University Hospital Zurich, Zurich, Switzerland., Whittle JR; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Personalised Oncology Division, Walter and Eliza Hall Institute, Parkville, VIC, Australia., Berger MS; Department of Neurological Surgery, UCSF Brain Tumor Center, University of California San Francisco, San Francisco, CA, USA; Weill Institute for Neuroscience, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Khasraw M; The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA. Electronic address: mustafa.khasraw@duke.edu.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Oct; Vol. 25 (10), pp. e512-e519.

ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors.

Autor: Zhang KY; Department of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA., Parker M; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA., Weber-Levine C; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA., Kalluri A; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA., Gonzalez-Gomez I; Department of Pathology, Johns Hopkins All Children's Hospital, Saint Petersburg, USA., Raabe E; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA., Dudley JC; Department of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA., Gocke C; Department of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA., Lin MT; Department of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA., Zou Y; Department of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA., Sherief M; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA., Kamson DO; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA., Holdhoff M; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, USA., Mukherjee D; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA., Croog V; Department of Radiation Oncology, Sibley Memorial Hospital, Washington, USA., Schreck KC; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA., Rincon-Torroella J; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA., Bettegowda C; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, USA., Eberhart CG; Department of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA., Bale T; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA., Lucas CG; Department of Pathology, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA. clucas7@jhmi.edu.

Publikováno v: Acta neuropathologica [Acta Neuropathol] 2024 Aug 14; Vol. 148 (1), pp. 19. Date of Electronic Publication: 2024 Aug 14.

Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.

Autor: Parker M; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Kazemi F; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Krishnakumar A; School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA., Horowitz MA; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Myneni S; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Liu A; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Schreck KC; Department of Neurology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA., Lucas CG; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Mukherjee D; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Publikováno v: Journal of neuropathology and experimental neurology [J Neuropathol Exp Neurol] 2024 Jun 20; Vol. 83 (7), pp. 579-585.

No drug holidays in BRAF ^V600E glioma patients: An argument for dose reduction of targeted therapies.

Autor: Bazer DA; National Cancer Institute, Neuro-Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA.; Department of Neurology and Oncology, Johns Hopkins University, Baltimore, Maryland, USA., Kolchinski A; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Bush NAO; Departments of Neurology and Neurological Surgery, University of California San Francisco, San Francisco, California, USA., Clarke JL; Departments of Neurology and Neurological Surgery, University of California San Francisco, San Francisco, California, USA., Bagley SJ; Department of Medicine, Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Schreck KC; Department of Neurology and Oncology, Johns Hopkins University, Baltimore, Maryland, USA.

Publikováno v: Neuro-oncology practice [Neurooncol Pract] 2024 May 24; Vol. 11 (5), pp. 660-664. Date of Electronic Publication: 2024 May 24 (Print Publication: 2024).